...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of International Medical Research >Cysteine-rich, angiogenic inducer, 61 expression in patients with ovarian epithelial carcinoma
【24h】

Cysteine-rich, angiogenic inducer, 61 expression in patients with ovarian epithelial carcinoma

机译：富含半胱氨酸的血管生成诱导剂在卵巢上皮癌患者中的表达61

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Objective Cysteine-rich, angiogenic inducer, 61 (CYR61) is a key gene in the transforming growth factor-β signalling pathway, which is involved in the development of many tumour types. This study aimed to clarify the status and clinical significance of CYR61 expression in patients with ovarian epithelial carcinoma. Methods Tissue from patients with ovarian epithelial carcinoma or benign ovarian tumours were investigated retrospectively for CYR61 expression at mRNA and protein levels, using reverse transcription–polymerase chain reaction and immunohistochemistry, respectively. Correlations between immunohistochemical scores and several clinicopathological parameters were investigated. Results In 50 patients with ovarian epithelial carcinoma and 50 patients with benign ovarian tumours, CYR61 expression on mRNA and protein levels was significantly higher in ovarian epithelial carcinoma tissue than in benign ovarian tissue. CYR61 expression was associated with regional lymph node metastases and progression of clinical disease stage. There was no difference in CYR61 expression between patients aged <50 years and ≥50 years. Conclusions CYR61 expression was significantly upregulated in ovarian carcinoma tissue compared with benign ovarian tumour tissue samples. Protein CYR61 levels were associated with lymph node metastases and Union for International Cancer Control stage. Protein CYR61 may be useful in targeted diagnosis and therapy, for patients with ovarian epithelial carcinoma.
机译：目的富含半胱氨酸的血管生成诱导剂61（CYR61）是转化生长因子-β信号转导途径中的关键基因，其参与多种肿瘤类型的发展。本研究旨在阐明CYR61在卵巢上皮癌患者中的表达及其临床意义。方法采用逆转录聚合酶链反应和免疫组织化学方法，分别对卵巢上皮癌或卵巢良性肿瘤患者组织中CYR61 mRNA和蛋白水平的表达进行回顾性研究。研究了免疫组织化学评分与一些临床病理参数之间的相关性。结果在50例卵巢上皮癌和50例卵巢良性肿瘤中，CYR61的mRNA和蛋白水平在卵巢上皮癌组织中明显高于在卵巢良性组织中。 CYR61表达与区域淋巴结转移和临床疾病分期有关。 CYR61表达在<50岁和≥50岁的患者之间没有差异。结论与卵巢良性肿瘤组织相比，卵巢癌组织中CYR61的表达明显上调。 CYR61蛋白水平与淋巴结转移和国际癌症控制分期有关。 CYR61蛋白可能对卵巢上皮癌患者有针对性的诊断和治疗。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号